Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a prospective, single-arm, single-center interventional study designed to evaluate the safety and efficacy of Elra-Isa-VR in patients with newly diagnosed ultra-high-risk multiple myeloma.
Epistemonikos ID: 0523e6dc3ab1a83006e8ddbdd90a3a0938f11420
First added on: Aug 27, 2026